ERAS
Price
$1.39
Change
-$0.03 (-2.11%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
396.57M
13 days until earnings call
KYMR
Price
$33.56
Change
+$2.86 (+9.32%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
2.18B
6 days until earnings call
Ad is loading...

ERAS vs KYMR

Header iconERAS vs KYMR Comparison
Open Charts ERAS vs KYMRBanner chart's image
Erasca
Price$1.39
Change-$0.03 (-2.11%)
Volume$35.15K
Capitalization396.57M
Kymera Therapeutics
Price$33.56
Change+$2.86 (+9.32%)
Volume$21.95K
Capitalization2.18B
ERAS vs KYMR Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERAS vs. KYMR commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Buy and KYMR is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (ERAS: $1.40 vs. KYMR: $33.56)
Brand notoriety: ERAS and KYMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 34% vs. KYMR: 165%
Market capitalization -- ERAS: $396.57M vs. KYMR: $2.18B
ERAS [@Biotechnology] is valued at $396.57M. KYMR’s [@Biotechnology] market capitalization is $2.18B. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileKYMR’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • KYMR’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than KYMR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 5 TA indicator(s) are bullish while KYMR’s TA Score has 4 bullish TA indicator(s).

  • ERAS’s TA Score: 5 bullish, 3 bearish.
  • KYMR’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than KYMR.

Price Growth

ERAS (@Biotechnology) experienced а +20.69% price change this week, while KYMR (@Biotechnology) price change was +29.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

ERAS is expected to report earnings on Aug 07, 2025.

KYMR is expected to report earnings on Aug 01, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KYMR($2.18B) has a higher market cap than ERAS($397M). KYMR YTD gains are higher at: -16.580 vs. ERAS (-43.426). ERAS has higher annual earnings (EBITDA): -151.33M vs. KYMR (-216.24M). KYMR has more cash in the bank: 489M vs. ERAS (319M). ERAS has less debt than KYMR: ERAS (52.9M) vs KYMR (87.8M). KYMR has higher revenues than ERAS: KYMR (47.1M) vs ERAS (0).
ERASKYMRERAS / KYMR
Capitalization397M2.18B18%
EBITDA-151.33M-216.24M70%
Gain YTD-43.426-16.580262%
P/E RatioN/AN/A-
Revenue047.1M-
Total Cash319M489M65%
Total Debt52.9M87.8M60%
TECHNICAL ANALYSIS
Technical Analysis
ERASKYMR
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 17 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
QGIAX24.35N/A
N/A
Pear Tree Quality Institutional
CAXIX17.40N/A
N/A
Catalyst/MAP Global Equity I
ALVGX9.99N/A
N/A
American Century Focused Lg Cap Val R5
FNNEX54.89N/A
N/A
American Funds New Economy 529-F-3
VCRQX13.90-0.02
-0.14%
NYLI CBRE Global Infrastructure Class R6

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with RVMD. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+2.90%
RVMD - ERAS
53%
Loosely correlated
+1.57%
XNCR - ERAS
53%
Loosely correlated
+2.07%
KYMR - ERAS
52%
Loosely correlated
+6.56%
BEAM - ERAS
50%
Loosely correlated
+3.87%
ELVN - ERAS
50%
Loosely correlated
-1.45%
More

KYMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, KYMR has been loosely correlated with CCCC. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if KYMR jumps, then CCCC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KYMR
1D Price
Change %
KYMR100%
+9.32%
CCCC - KYMR
63%
Loosely correlated
N/A
NRIX - KYMR
57%
Loosely correlated
-0.78%
IMNM - KYMR
55%
Loosely correlated
+0.24%
RVMD - KYMR
54%
Loosely correlated
+3.04%
RCKT - KYMR
54%
Loosely correlated
+4.06%
More